Guidelines for Bone Health After Fragility Fracture

Abstract

Fragility fractures represent a significant clinical challenge, serving as a sentinel event for underlying osteoporosis and future fracture risk. Optimal management of bone health post-fragility fracture is vital for preventing subsequent fractures, improving patient outcomes, and reducing healthcare burden. This comprehensive review synthesizes current evidence, recent guidelines, and practice recommendations for bone health maintenance after fragility fractures, focusing on epidemiology, pathophysiology, risk stratification, clinical evaluation, diagnostic strategies, treatment, and emerging therapies. The article offers insights applicable to diverse clinical settings, providing actionable guidance for healthcare professionals managing these high-risk patients.

Introduction

Fragility fractures, defined as fractures resulting from low-energy trauma, most commonly affect the elderly population and are closely linked with osteoporosis. These fractures are associated with increased morbidity, mortality, and significant healthcare expenditures. Ensuring bone health post-fragility fracture is essential not only to improve individual patient outcomes but also to prevent a cascade of subsequent fractures. This review aims to provide clinicians with an evidence-based, guideline-driven framework for the assessment and management of bone health following a fragility fracture, integrating recent advances and practical considerations into daily practice.

Epidemiology / Disease Burden

Globally, fragility fractures constitute a major health concern, with approximately 9 million osteoporotic fractures occurring annually. Hip, vertebral, and distal radius fractures are the most prevalent, with hip fractures carrying the highest morbidity and mortality. The lifetime risk of sustaining a fragility fracture in individuals over the age of 50 is estimated at 40-50% for women and 13-22% for men. The economic impact is substantial, encompassing direct medical costs, loss of independence, and increased long-term care needs. Importantly, a prior fragility fracture is a strong predictor of future fracture, underscoring the need for prompt secondary prevention.

Pathophysiology

Fragility fractures occur when bone strength is insufficient to withstand minor trauma, primarily due to decreased bone mineral density (BMD) and deterioration of bone microarchitecture. Osteoporosis, characterized by low BMD and compromised bone quality, results from an imbalance between bone resorption and formation. Age-related hormonal changes, particularly reduced estrogen in postmenopausal women and declining testosterone in men, accelerate bone loss. Additionally, alterations in calcium and vitamin D metabolism, chronic inflammation, and secondary causes such as glucocorticoid use or endocrine disorders can further impair bone integrity.

Risk Factors

Major risk factors for fragility fractures include advanced age, female sex, family history of osteoporosis, low body mass index, previous fracture, smoking, excessive alcohol intake, physical inactivity, and chronic diseases like rheumatoid arthritis or diabetes. Medications such as corticosteroids, anticonvulsants, and aromatase inhibitors also increase fracture risk. Secondary osteoporosis should be considered in patients with atypical fracture patterns or those with underlying systemic illnesses. Identifying and addressing modifiable risk factors is central to comprehensive post-fracture care.

Clinical Features

Fragility fractures may present with acute pain, loss of function, and deformity at the affected site. Vertebral fractures often manifest as back pain, height loss, or kyphosis, while hip fractures typically present with inability to bear weight and shortened, externally rotated lower limb. Notably, some vertebral fractures remain clinically silent and may only be detected incidentally. The occurrence of any fragility fracture mandates evaluation for underlying osteoporosis and risk of subsequent fractures.

Diagnosis

Diagnosis of osteoporosis post-fragility fracture relies on clinical assessment, imaging, and laboratory investigations. Dual-energy X-ray absorptiometry (DXA) is the gold standard for measuring BMD. The World Health Organization defines osteoporosis as a T-score ≤ -2.5. Vertebral fracture assessment (VFA) using lateral spine imaging can identify asymptomatic vertebral fractures. Laboratory evaluation should exclude secondary causes, with tests including serum calcium, phosphate, 25-hydroxyvitamin D, renal and liver function, thyroid-stimulating hormone, and parathyroid hormone levels. Fracture risk assessment tools such as FRAX integrate clinical risk factors with BMD to estimate 10-year fracture probability.

Treatment & Management

Management of bone health post-fragility fracture is multifaceted, comprising pharmacological and non-pharmacological interventions. All patients should receive counseling on adequate dietary calcium and vitamin D intake, fall prevention strategies, and lifestyle modifications (e.g., smoking cessation, reduced alcohol consumption, and regular weight-bearing exercise). First-line pharmacologic therapy includes antiresorptive agents such as bisphosphonates (alendronate, risedronate, zoledronic acid) and denosumab. Anabolic agents like teriparatide, abaloparatide, and romosozumab may be considered in patients at very high fracture risk or with multiple fractures. Therapy selection should be individualized, considering patient comorbidities, renal function, preferences, and risk profile. Monitoring adherence and periodic reassessment of BMD are crucial for optimizing long-term outcomes.

Recent Advances / Emerging Therapies

Recent advances in osteoporosis therapeutics have expanded the armamentarium for secondary fracture prevention. Romosozumab, a monoclonal antibody targeting sclerostin, has demonstrated superior efficacy in increasing BMD and reducing vertebral and nonvertebral fractures compared to traditional agents. Sequential therapy, initiating with anabolic agents followed by antiresorptives, is gaining traction for patients at highest risk. Novel biomarkers and imaging techniques are under investigation to refine fracture risk prediction and personalize therapy. Multidisciplinary fracture liaison services (FLS) have proven effective in improving post-fracture care, increasing osteoporosis diagnosis and treatment rates, and reducing future fractures.

Guideline Recommendations

Current international guidelines, including those from the National Osteoporosis Foundation (NOF), International Osteoporosis Foundation (IOF), and American Association of Clinical Endocrinology (AACE), advocate for prompt assessment and initiation of osteoporosis therapy in all patients with fragility fractures, regardless of BMD. Calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) supplementation are universally recommended. Bisphosphonates remain first-line, with alternative agents for those intolerant or contraindicated. Duration of therapy should be individualized, and drug holidays may be considered after 3-5 years of bisphosphonate use in low-risk patients. Regular re-evaluation for efficacy, side effects, and adherence is essential. Coordinated care models, such as FLS, are strongly endorsed to ensure comprehensive post-fracture management.

Conclusion

Fragility fractures signify underlying skeletal fragility and mandate proactive, guideline-based interventions to restore and preserve bone health. Early identification of risk factors, timely diagnosis, and initiation of effective pharmacologic and non-pharmacologic therapies are critical steps in reducing the risk of subsequent fractures. Recent therapeutic advances and coordinated care models have significantly improved outcomes, yet implementation gaps persist. Continuous education, adherence to evidence-based guidelines, and multidisciplinary collaboration are essential to optimize bone health and patient quality of life after fragility fracture.